Table 1.
Descriptions of the targeted corpora screened by Seek & Blastn with manual verification of nucleotide sequence reagent identities.
| Single gene knockdown (SGK) | miR-145 | Cisplatin + Gemcitabine (C + G) | ||||
|---|---|---|---|---|---|---|
| Corpus | Problematic | Corpus | Problematic | Corpus | Problematic | |
| Number of articles (% of corpus) | 174 (100%) | 75 (43%) | 50 (100%) | 31 (62%) | 100 (100%) | 51 (50%) |
| Number of journals | 83 | 42 | 35 | 25 | 48 | 31 |
| Publication year median (range) | 2015 (2006–2019)a | 2015 (2010–2019) | 2017 (2009–2019) | 2017 (2009–2019) | 2017 (2008–2019) | 2017 (2009–2019) |
| Journal impact factor at publication year median (range) | 2.204 (0.098–8.459) | 1.778 (0.098–5.712) | 3.34 (0.700–9.050) | 3.23 (0.700–8.278) | 3.571 (1.099–10.391) | 3.041 (1.099–8.579) |
| Number of sequences/article median (range) | 6 (0–24) | 6 (1–24) | 11 (4–46) | 10 (4–46) | 11 (2–71) | 12 (2–70) |
| Number of incorrect sequences/article median (range) | ND | 1 (1–8) | ND | 1 (1–5) | ND | 2 (1–8) |
| Articles from China proportion (%) | 159/174 (91%) | 73/75 (97%) | 44/50 (88%) | 31/31 (100%) | 90/100 (90%) | 50/51 (98%) |
| Articles from China affiliated with hospitals proportion (%) | 147/159 (92%) | 68/73 (93%) | 40/44 (91%) | 28/31 (90%) | 82/90 (91%) | 48/50 (96%) |
| Articles from all other countries affiliated with hospitals proportion (%) | 6/15 (40%) | 0/2 (0%) | 0/6 (0%) | 0/3 (0%) | 1/10 (10%) | 0/1 (0%) |
| Articles with post-publication noticesb proportion (%) | 20/174 (12%) | 13/75 (17%) | 1/50 (2%) | 1/31 (3%) | 1/100 (1%) | 1/51 (2%) |
a
SGK articles were published until June 2019.
b
Post-publication notices include retractions, expressions of concern and corrections.